EGFR and cancer: Together, our results indicate that TMEM52B suppression promotes the internalization and sustained accumulation of EGFR in the endosomal compartment in response to EGF treatment, resulting in enhanced activation of EGFR and its downstream signaling mediators AKT and ERK1/2 to drive cancer cell survival and invasion.